We spoke to Sanofi SVP Brendan O’Callaghan about the future of medicine in the context of innovations in data science, artificial intelligence and the unlocking of the human genome.

As SVP and global head of biologics platform at Sanofi, Brendan O’Callaghan is at the coalface of developments in personalised medicine. He spoke to Siliconrepublic.com editor John Kennedy at BioPharma Ambition, a Dublin event that welcomed international policy leaders, renowned researchers and senior industry personnel to discuss the future of biopharma in Ireland and beyond.

O’Callaghan said that the Irish-based company’s current research is looking to use the body’s own proteins to unlock medicinal properties inside us. However, he believes it will be some time before we see personalised medicine treatments becoming as common as a regular check-up.


Words by Colm Gorey